Nicox Confirms Eligibility for the PEA-PME Scheme
Nicox SA, an international ophthalmology company, has confirmed its eligibility for the PEA-PME scheme for the upcoming year. This confirmation allows investors to continue to include the company's shares in this tax scheme dedicated to small and medium-sized stocks.
Eligibility Assessment
Nicox has assessed its eligibility criteria for the PEA-PME according to the provisions set by the monetary and financial code. The company's shares, listed on Euronext Growth Paris (ticker: ALCOX), retain their eligibility status for the upcoming year, offering investors the same tax advantages as the classic PEA scheme.
Innovative Ophthalmic Solutions
Nicox is developing innovative solutions in the field of eye health. The group notably has NCX 470, an eye drop in advanced development phase aimed at reducing intraocular pressure in patients with glaucoma, licensed to international partners. Nicox also markets VYZULTA® in the United States and across 15 other territories, as well as ZERVIATE® for allergic conjunctivitis in several markets.
